FDA Vaccine Panel to Consider Reformulating COVID-19 Vaccines

XFG strains have been dominant in the United States in recent months.

A child receives a dose of the Pfizer BioNTech COVID-19 vaccine at the Fairfax County Government Center in Annandale, Va., on Nov. 4, 2021. Chip Somodevilla/Getty Images

The Food and Drug Administration’s panel of vaccine advisers will consider which COVID-19 strains the agency should direct manufacturers to target in the fall.

The FDA Vaccines and Related Biological Products Advisory Committee is scheduled to meet on May 28 and vote on whether vaccines should be reformulated to target XFG variants.